Afatinib in Advanced NRG1-Rearranged Malignancies
NCT04410653
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
3
Enrollment
OTHER
Sponsor class
Conditions
Metastatic and Locally Advanced NRG1-rearranged Malignancies
Interventions
DRUG:
Afatinib 40 MG
Sponsor
German Cancer Research Center
Collaborators
[object Object]